Program
brincidofovir
Also written as “Brincidofovir”, “CMX001” and “SyB V-1901”.
Its studies are mostly in Adenoviridae Infections · Cytomegalovirus Infections · Lymphoma, T-Cell · Smallpox · Kidney Diseases, led by 3 companies.
Drug pageBrincidofovir: every studyAll 22 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jazz Pharmaceuticalsits history only | 140 open or running | phase 3since Jun 11, 2010 | Oct 23, 2008 | none ahead |
| SymBio Pharmaceuticals | 41 open or running | phase 3since Jan 20, 2026 | Aug 29, 2020 | Jan 31, 2028phase 3 · NCT07387367 |
| Emergent BioSolutionsits history only | 10 open or running | phase 1since Jun 5, 2023 | Jun 5, 2023 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of SymBio Pharmaceuticals only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 29, 2020First study: phase 1 study in Drug Drug InteractionFirst studyNCT04542252 · 13 enrolled · Japan
- Aug 16, 2022Phase 2 study in Kidney DiseasesNCT05511779 · 1 enrolled · Japan
- Dec 24, 2024Phase 2 study in RecurrenceNCT06761677 · 43 enrolled · China, Japan, Singapore
- Jan 20, 2026Phase 3 study in Adenoviridae InfectionsPhase 3 reachedNCT07387367 · 180 planned · United States, Austria, Belgium and more
Ahead
- Jan 31, 2028Primary completion: phase 3 study in Adenoviridae InfectionsNCT07387367
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“DNA polymerase inhibitor”ChEMBL 37, by rule
Studies
All 4 SymBio Pharmaceuticals leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07387367Adenoviridae Infections · United States, Austria, Belgium and more | 3 | Recruiting | Jan 31, 2028 | 180 |
| NCT06761677Recurrence · China, Japan, Singapore | 2 | Suspended | Oct 23, 2027 | 43 |
| NCT05511779Kidney Diseases · Japan | 2 | Terminated | Apr 13, 2023 | 1 |
| NCT04542252Drug Drug Interaction · Japan | 1 | Completed | Dec 22, 2020 | 13 |
How it is read
Names in the registry
- “Brincidofovir”, 15 entries
- “CMX001”, 3 entries
- “SyB V-1901”, 1 entry
Conditions, from the studies’ own filings
- Adenoviridae Infections, 5 studies
- Cytomegalovirus Infections, 3 studies
- Lymphoma, T-Cell, 1 study
- Smallpox, 1 study
- Kidney Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.